Literature DB >> 29860627

IL-2 antibodies in type 1 diabetes and during IL-2 therapy.

Guillaume Churlaud1,2, Michelle Rosenzwajg1,2, Patrice Cacoub1,2,3, David Saadoun1,2,3, Dominique Valteau-Couanet4, Nathalie Chaput5,6, Alberto Pugliese7,8,9, David Klatzmann10,11.   

Abstract

Entities:  

Keywords:  Autoantibodies; Autoimmune disease; Autoimmunity; IL-2; Type 1 diabetes

Mesh：

Substances：

Year:  2018        PMID： 29860627     DOI： 10.1007/s00125-018-4649-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  10 in total

Review 1.  High avidity cytokine autoantibodies in health and disease: pathogenesis and mechanisms.

Authors:  Masato Watanabe; Kanji Uchida; Kazuhide Nakagaki; Bruce C Trapnell; Koh Nakata
Journal:  Cytokine Growth Factor Rev       Date:  2010-04-22       Impact factor: 7.638

2.  Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.

Authors:  Michelle Rosenzwajg; Guillaume Churlaud; Roberto Mallone; Adrien Six; Nicolas Dérian; Wahiba Chaara; Roberta Lorenzon; S Alice Long; Jane H Buckner; Georgia Afonso; Hang-Phuong Pham; Agnès Hartemann; Aixin Yu; Alberto Pugliese; Thomas R Malek; David Klatzmann
Journal:  J Autoimmun       Date:  2015-01-26       Impact factor: 7.094

3.  Autoantibody binding in liquid phase to IL-2 in human sera is not type 1 diabetes specific.

Authors:  Ilaria Marzinotto; Daniela Liberati; Cristina Brigatti; Riccardo Bonfanti; Angela Stabilini; Paolo Monti; Emanuele Bosi; Lorenzo Piemonti; Vito Lampasona
Journal:  Diabetologia       Date:  2017-07-19       Impact factor: 10.122

4.  Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.

Authors:  David Saadoun; Michelle Rosenzwajg; Florence Joly; Adrien Six; Fabrice Carrat; Vincent Thibault; Damien Sene; Patrice Cacoub; David Klatzmann
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

Review 5.  The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases.

Authors:  David Klatzmann; Abul K Abbas
Journal:  Nat Rev Immunol       Date:  2015-04-17       Impact factor: 53.106

Review 6.  Treatment-induced antibodies to interleukin-2.

Authors:  O Prümmer
Journal:  Biotherapy       Date:  1997

7.  Interleukin-2 binding proteins in sera from normal subjects and multiple sclerosis patients.

Authors:  J L Trotter; C A Damico; A L Trotter; K G Collins; A H Cross
Journal:  Neurology       Date:  1995-11       Impact factor: 9.910

8.  Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.

Authors:  Agnès Hartemann; Gilbert Bensimon; Christine A Payan; Sophie Jacqueminet; Olivier Bourron; Nathalie Nicolas; Michèle Fonfrede; Michelle Rosenzwajg; Claude Bernard; David Klatzmann
Journal:  Lancet Diabetes Endocrinol       Date:  2013-10-08       Impact factor: 32.069

9.  Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis.

Authors:  A Meager; M Wadhwa; P Dilger; C Bird; R Thorpe; J Newsom-Davis; N Willcox
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

10.  Loss of immune tolerance to IL-2 in type 1 diabetes.

Authors:  Louis Pérol; John M Lindner; Pamela Caudana; Nicolas Gonzalo Nunez; Audrey Baeyens; Andrea Valle; Christine Sedlik; Delphine Loirat; Olivier Boyer; Alain Créange; José Laurent Cohen; Ute Christine Rogner; Jun Yamanouchi; Martine Marchant; Xavier Charles Leber; Meike Scharenberg; Marie-Claude Gagnerault; Roberto Mallone; Manuela Battaglia; Pere Santamaria; Agnès Hartemann; Elisabetta Traggiai; Eliane Piaggio
Journal:  Nat Commun       Date:  2016-10-06       Impact factor: 14.919
  10 in total
  2 in total

Review 1.  Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2020-08-24       Impact factor: 3.199

Review 2.  Interleukin-2 and regulatory T cells in rheumatic diseases.

Authors:  Antonios G A Kolios; George C Tsokos; David Klatzmann
Journal:  Nat Rev Rheumatol       Date:  2021-11-02       Impact factor: 20.543
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.